Randomized, Phase II study of pemetrexed plus bevacizumab versus pemetrexed alone after treatment with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous, non-small cell lung cancer: TORG (thoracic oncology research group) 1321.
Takashi KasaiKiyoshi MoriYoichi NakamuraNobuhiko SekiYasuko IchikawaHaruhiro SaitoTetsuro KondoKazuo NishikawaSatoshi OtsuAkihiro BesshoHiroshi TanakaHiroyuki YamaguchiTakayuki KaburagiHisao ImaiKeita MoriJunya OhtakeHiroaki OkamotoPublished in: Cancer medicine (2023)
Addition of bevacizumab to pemetrexed as maintenance therapy prolonged PFS in patients with untreated, advanced, non-squamous NSCLC. Furthermore, an early response to induction therapy and pretreatment M-MDSC counts may be related to the survival benefit of the addition of bevacizumab to the combination of cisplatin and pemetrexed.
Keyphrases
- small cell lung cancer
- advanced non small cell lung cancer
- metastatic colorectal cancer
- phase ii study
- open label
- brain metastases
- high grade
- epidermal growth factor receptor
- low grade
- stem cells
- palliative care
- placebo controlled
- peripheral blood
- randomized controlled trial
- phase iii
- radiation therapy
- squamous cell carcinoma
- tyrosine kinase